e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?
McGoon Michael D.
Source:
Eur Respir J 2014; 43: 1556-1559
Journal Issue:
June
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
McGoon Michael D.. Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?. Eur Respir J 2014; 43: 1556-1559
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated
Source: Eur Respir J, 57 (1) 2004258; 10.1183/13993003.04258-2020
Year: 2021
Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready?
Source: Eur Respir J 2014; 44: 1404-1407
Year: 2014
Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension
Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020
Year: 2021
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 408-417
Year: 2016
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Source: Eur Respir J 2014; 43: 1691-1697
Year: 2014
The role of combination therapy in managing pulmonary arterial hypertension
Source: Eur Respir Rev 2014; 23: 469-475
Year: 2014
Pulmonary arterial hypertension: combination therapy in the modern management era
Source: Eur Respir Rev 2010 19: 348-349
Year: 2010
Optimal management of severe pulmonary arterial hypertension
Source: Eur Respir Rev 2011; 20: 254-261
Year: 2011
Initial dual oral combination therapy in pulmonary arterial hypertension
Source: Eur Respir J 2016; 47:1727-1736
Year: 2016
Combination therapy for pulmonary arterial hypertension: still more questions than answers
Source: Eur Respir J 2004; 24: 339-340
Year: 2004
Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better?
Source: Eur Respir J 2006 Oct 01;28(4):683-686
Year: 2006
ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad
Source: Eur Respir J, 51 (6) 1800848; 10.1183/13993003.00848-2018
Year: 2018
Pulmonary arterial hypertension: tailoring treatment to risk in the current era
Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017
Year: 2017
Pulmonary arterial hypertension: treatment options
Source: International Congress 2018 – ME10 Pulmonary arterial hypertension: treatment options FULLY BOOKED
Year: 2018
Challenges in the diagnosis and treatment of pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21: 313-320
Year: 2012
Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy
Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020
Year: 2021
Thrombo-embolic pulmonary hypertension: which treatment should we choose? / Hypertension pulmonaire thrombo-embolique: quel traitement choisir ?
Source: International Congress 2018 – French Programme 2018: Part II
Year: 2018
Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future?
Source: Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019
Year: 2019
?-blockers in pulmonary arterial hypertension: generation might matter
Source: Eur Respir J 2016; 47: 682-684
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept